热灌注、贝伐珠单抗联合顺铂在妇科肿瘤恶性胸腹腔积液的疗效观察  

Observation on the efficacy of thermoperfusion combined with bevacizumab combined with cisplatin in patients with malignant pleuroabdominal effusion in gynecological tumors

作　　者：姜鑫 黄健华 Jiang Xin;Huang Jianhua(Department of Chemotherapy,Yixing Cancer Hospital,Yixing 214200,China)

机构地区：[1]宜兴市肿瘤医院化疗科,江苏宜兴214200

出　　处：《实用妇科内分泌电子杂志》2023年第24期49-51,共3页Electronic Journal of Practical Gynecological Endocrinology

摘　　要：目的分析妇科肿瘤恶性胸腹腔积液治疗中热灌注、贝伐珠单抗、顺铂联合治疗的应用价值。方法选取80例妇科肿瘤恶性胸腹腔积液患者,按照电脑随机数法予以分组,每组40例。对照组予以热灌注联合顺铂治疗,研究组在对照组基础上联合贝伐珠单抗治疗。对比两组治疗效果。结果研究组治疗总有效率为82.50%,高于对照组的60.00%(P<0.05)。研究组生活质量改善率为67.50%,高于对照组的40.00%(P<0.05)。研究组毒副反应发生率为17.50%,与对照组的20.00%比较,差异无统计学意义(P>0.05)。结论顺铂、热灌注联合贝伐珠单抗治疗妇科肿瘤恶性胸腹腔积液患者能够在更大程度上提升临床有效性,改善患者生活质量,且不会增加毒副反应,值得临床推广。Objective To analyze the application value of thermoperfusion,bevacizumab and cisplatin in the treatment of malignant pleuroperitoneal effusion of gynecological tumors.Methods 80 patients with malignant pleuroceliac effusion of gynecological tumors were selected and divided into 40 cases in each group according to computer random number method.The control group was treated with thermoperfusion combined with cisplatin,and the study group was treated with bevacizumab on the basis of the control group.The therapeutic effect of the two groups was compared.Results The total effective rate of the study group was 82.50%,which was higher than 60.00%of the control group(P<0.05).The improvement rate of quality of life in the study group was 67.50%,which was higher than that in the control group(40.00%)(P<0.05).The incidence of toxic and side effects in the study group was 17.50%,compared with 20.00%in the control group,the difference was not statistically significant(P>0.05).Conclusion The combination of cisplatin,thermoperfusion and bevacizumab in the treatment of patients with malignant chest and abdominal effusion of gynecological tumors can improve clinical effectiveness to a greater extent,improve the quality of life of patients,and will not increase toxic side effects,which is worthy of clinical promotion.

关 键 词：热灌注 贝伐珠单抗 顺铂 恶性胸腹腔积液 

分 类 号：R737.3[医药卫生—肿瘤]